Q3 Earnings Estimate for Climb Bio Issued By William Blair

Climb Bio, Inc. (NASDAQ:CLYM) – Equities research analysts at William Blair issued their Q3 2025 earnings estimates for Climb Bio in a research note issued on Thursday, October 16th. William Blair analyst M. Phipps expects that the company will earn ($0.14) per share for the quarter. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Climb Bio’s current full-year earnings is ($1.57) per share. William Blair also issued estimates for Climb Bio’s Q4 2025 earnings at ($0.15) EPS, FY2025 earnings at ($0.72) EPS, FY2026 earnings at ($0.73) EPS, FY2027 earnings at ($0.88) EPS, FY2028 earnings at ($1.09) EPS and FY2029 earnings at ($1.47) EPS.

Climb Bio (NASDAQ:CLYM) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.06.

A number of other equities analysts also recently weighed in on CLYM. HC Wainwright began coverage on shares of Climb Bio in a research note on Monday, October 13th. They set a “buy” rating and a $9.00 price target on the stock. Baird R W raised shares of Climb Bio to a “strong-buy” rating in a research note on Friday, August 15th. BTIG Research reaffirmed a “buy” rating and set a $8.00 price target on shares of Climb Bio in a research note on Thursday, October 16th. Robert W. Baird assumed coverage on shares of Climb Bio in a research note on Friday, August 15th. They set an “outperform” rating and a $9.00 price target on the stock. Finally, Wall Street Zen raised shares of Climb Bio from a “sell” rating to a “hold” rating in a research report on Monday, October 6th. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $9.20.

Climb Bio Stock Up 20.2%

NASDAQ:CLYM opened at $2.32 on Monday. The company has a market cap of $157.20 million, a P/E ratio of -3.31 and a beta of -0.07. Climb Bio has a fifty-two week low of $1.05 and a fifty-two week high of $5.00. The firm’s 50 day moving average is $2.11 and its two-hundred day moving average is $1.59.

Institutional Investors Weigh In On Climb Bio

Large investors have recently made changes to their positions in the business. AQR Capital Management LLC acquired a new stake in Climb Bio during the 1st quarter valued at $27,000. XTX Topco Ltd acquired a new stake in Climb Bio during the 1st quarter valued at $34,000. Diadema Partners LP grew its holdings in Climb Bio by 4.8% during the 2nd quarter. Diadema Partners LP now owns 702,135 shares of the company’s stock valued at $871,000 after purchasing an additional 32,332 shares in the last quarter. Qube Research & Technologies Ltd acquired a new stake in Climb Bio during the 2nd quarter valued at $43,000. Finally, Marshall Wace LLP acquired a new stake in Climb Bio during the 2nd quarter valued at $46,000. Institutional investors and hedge funds own 69.76% of the company’s stock.

Climb Bio Company Profile

Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.